FDA approves new painkiller designed to avoid opioid addiction risk
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to treating pain in more than 20 years,
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
NBC News on MSN13d
'Will it really work?': Young sickle cell patient among the first to start new gene therapySince two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
2h
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback